Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various huma…
$0.77-5.63%
报价 2026-11-13
市值
$139.4M
EV
$118.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -88.4%
$0.68$6.69
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CMPXCompass Therapeutics, Inc. | $139.4M | -5.6% | -125.5% | 0% | – | – | – | |
| OMEROmeros Corporation | $1.27B | -2.8% | +5000.0% | 95.8% | 9.7x | 10.7x | – | |
| CRVSCorvus Pharmaceuticals, Inc. | $897.5M | +0.2% | +100.0% | 0% | – | – | – | |
| LXRXLexicon Pharmaceuticals, Inc. | $797M | -1.6% | -21.3% | 98.6% | – | – | – | |
| FDMT4D Molecular Therapeutics, Inc. | $675.6M | +0.9% | -60.3% | 42% | – | – | – | |
| MNPRMonopar Therapeutics Inc. | $487.9M | -0.9% | – | 0% | – | – | – | |
| FULCFulcrum Therapeutics, Inc. | $288M | +2.4% | -98.9% | 0% | – | – | – | |
| OCGNOcugen, Inc. | $280.9M | -5.2% | -5.4% | 88.5% | – | – | – | |
| BCYCBicycle Therapeutics plc | $235.9M | -2.3% | – | 100% | – | – | – | |
| 同行中位数 | – | – | -13.3% | 65.3% | 9.7x | 10.7x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。